Zobrazeno 1 - 10
of 446
pro vyhledávání: '"Kazuo Fujihara"'
Autor:
Takashi Yamamura, Noriko Isobe, Izumi Kawachi, Chiyoko Nohara, Yusei Miyazaki, Minami Tomita, Takahiko Tsumuraya, Katsuhisa Yamashita, Jin Nakahara, Ichiro Nakashima, Kazuo Fujihara
Publikováno v:
Neurology and Therapy, Vol 13, Iss 5, Pp 1361-1383 (2024)
Abstract Introduction Satralizumab, an anti-interleukin-6 receptor antibody, is approved in Japan for relapse prevention in neuromyelitis optica spectrum disorder (NMOSD) and is undergoing post-marketing surveillance (PMS) of clinical use. We aimed t
Externí odkaz:
https://doaj.org/article/cacd9763b99f4053953f8a9a3963e85e
Autor:
Ken Sakushima, M.D., M.P.H., Ph.D., Harumasa Nakamura, M.D., Ph.D., Kazuo Fujihara, M.D., Ph.D.
Publikováno v:
Neurotherapeutics, Vol 21, Iss 4, Pp e00406- (2024)
Externí odkaz:
https://doaj.org/article/b983b4e9ca5844448c248f6c2b5691c4
Autor:
Chihiro Namatame, Yoichiro Abe, Yoshiki Miyasaka, Yoshiki Takai, Yuki Matsumoto, Toshiyuki Takahashi, Tomoji Mashimo, Tatsuro Misu, Kazuo Fujihara, Masato Yasui, Masashi Aoki
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 15, p 8169 (2024)
Conventional rodent neuromyelitis optica spectrum disorder (NMOSD) models using patient-derived immunoglobulin G (IgG) are potentially affected by the differences between the human and rodent aquaporin-4 (AQP4) extracellular domains (ECDs). We hypoth
Externí odkaz:
https://doaj.org/article/c5b569515a6744dba00b577ec6478122
Autor:
Tetsuya Akaishi, Tatsuro Misu, Kazuo Fujihara, Kumi Nakaya, Naoki Nakaya, Tomohiro Nakamura, Mana Kogure, Rieko Hatanaka, Fumi Itabashi, Ikumi Kanno, Kimihiko Kaneko, Toshiyuki Takahashi, Juichi Fujimori, Yoshiki Takai, Shuhei Nishiyama, Tadashi Ishii, Masashi Aoki, Ichiro Nakashima, Atsushi Hozawa
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-8 (2023)
Abstract White blood cell (WBC) count profiles in anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4-NMOSD) and anti-myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) are still unknown. This study ev
Externí odkaz:
https://doaj.org/article/7008886e2ba74a87a069dffcecd429d7
Autor:
Jyh Yung Hor, Kazuo Fujihara
Publikováno v:
Frontiers in Neurology, Vol 14 (2023)
Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) is an inflammatory demyelinating disease of the central nervous system (CNS) with the presence of conformation-sensitive antibodies against MOG. The spectrum of MOGAD inclu
Externí odkaz:
https://doaj.org/article/7e382d18a33048618b344e40314ad1a1
Publikováno v:
Frontiers in Neurology, Vol 14 (2023)
Myelin oligodendrocyte glycoprotein (MOG) is expressed on the outermost layer of the myelin sheath in the central nervous system. Recently, the clinical concept of MOG antibody-associated disease (MOGAD) was established based on the results of human
Externí odkaz:
https://doaj.org/article/cfd436fb3b2c49e587bf42b3abe3cd2a
Autor:
Ralf Gold, Michael Barnett, Andrew Chan, Huiyu Feng, Kazuo Fujihara, Gavin Giovannoni, Xavier Montalbán, Fu-Dong Shi, Mar Tintoré, Qun Xue, Chunsheng Yang, Hongyu Zhou
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 16 (2023)
Dimethyl fumarate (DMF) is a widely used oral disease-modifying therapy for multiple sclerosis (MS). Its efficacy and safety profiles are supported by over a decade of experience. Differences exist between Asia and Europe/United States in the prevale
Externí odkaz:
https://doaj.org/article/8162bf3228324333936e05bd45337795
Autor:
Ichiro Nakashima, Jin Nakahara, Hiroaki Yokote, Yasuhiro Manabe, Kazumi Okamura, Kou Hasegawa, Kazuo Fujihara
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 16 (2023)
Background: The terminal complement C5 inhibitor eculizumab is approved in Japan for relapse prevention in aquaporin-4 antibody-positive (AQP4+) neuromyelitis optica spectrum disorder (NMOSD) and is undergoing mandatory post-marketing surveillance (P
Externí odkaz:
https://doaj.org/article/be2999c2978d49bba3a3526b7b8d1cc4
Publikováno v:
Precision and Future Medicine, Vol 6, Iss 2, Pp 105-116 (2022)
The discovery of novel autoantibodies in neurological disorders contributes to a better understanding of its pathogenesis, improves the accuracy of diagnosis, and leads to new treatment strategies. Advances in techniques for the screening and detecti
Externí odkaz:
https://doaj.org/article/42613de2dd4142179a7d4cf62ad20213
Autor:
Jeffrey L. Bennett, Kazuo Fujihara, Ho Jin Kim, Romain Marignier, Kevin C. O'Connor, Robert C. Sergott, Anthony Traboulsee, Heinz Wiendl, Jens Wuerfel, Scott S. Zamvil, Veronica G. Anania, Regine Buffels, Thomas Künzel, Annemarie N. Lekkerkerker, Siân Lennon-Chrimes, Sean J. Pittock
Publikováno v:
Frontiers in Neurology, Vol 14 (2023)
BackgroundNeuromyelitis optica spectrum disorder (NMOSD) is a rare, autoimmune disease of the central nervous system that produces acute, unpredictable relapses causing cumulative neurological disability. Satralizumab, a humanized, monoclonal recycli
Externí odkaz:
https://doaj.org/article/65073f7848d74c30812b90f40057ec13